AL 아밀로이드증 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 13.0%로 57억 4,000만 달러로 성장합니다. 예측 기간 중 예상되는 성장은 혈구 DNA 돌연변이 증가, 의료 인프라 확대, 다발성골수종 발병률 증가, 병용요법 도입, 대량 화학요법 사용 증가 등의 요인에 의해 이루어질 것으로 예측됩니다. 이 기간의 주요 동향으로는 진단 기술의 발전, 약물전달 기술 혁신, 혈액 검사 개선, 표적 치료법 개발, 진단에 인공지능(AI)의 통합 등을 들 수 있습니다.
혈장 세포 장애의 유병률 증가는 AL 아밀로이드증 시장의 성장을 가속할 것으로 예측됩니다. 형질세포 장애는 비정상적인 형질세포가 과도하거나 불규칙한 항체를 생산하여 장기 손상을 유발할 수 있는 질환입니다. 고령화, 평균 수명 증가, 진단 기술의 발전 등의 요인이 이러한 질환의 발생률 증가에 기여하고 있습니다. 형질 세포 장애로 인한 AL 아밀로이드증은 특히 비정상적인 경쇄 단백질의 과잉 생산으로 인해 발생합니다. 이는 장기 및 조직에 아밀로이드 침착물이 축적되어 형질 세포 이상증의 영향을 더욱 악화시킵니다. 예를 들어 2024년 8월 미국암협회(ACS)는 2024년에 약 35,780명의 다발성골수종 신규 환자가 진단될 것으로 예상되며, 그 중 남성 19,520명, 여성 16,260명, 남성 7,020명, 여성 5,520명 등 약 12,540명이 사망할 것으로 예상된다고 보고했습니다. 보고했습니다. 그 결과, 형질세포 질환의 유병률 증가가 AL 아밀로이드증 시장 확대를 주도하고 있습니다.
AL 아밀로이드증 치료제 시장은 치료 효과와 환자 예후를 개선하기 위해 차세대 B세포 성숙항원(BCMA) 지향성 CAR T세포 치료제와 같은 혁신적인 치료법 개발에 집중하고 있습니다. 공격하도록 환자의 T세포를 변형시키는 첨단 면역요법입니다. 예를 들어 2023년 9월, 미국 바이오제약회사 이믹스 바이오파마는 생명을 위협하는 혈액질환인 AL 아밀로이드증 치료를 위한 차세대 CAR-T 세포치료제 NXC-201을 미국 식품의약국(FDA)으로부터 승인받았습니다. 임상에서 유망한 결과를 보였으며, 혈액학적 반응률은 100%로 기존 치료에 반응하지 않던 환자에서도 장기가 개선되었습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 AL 아밀로이드증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 AL 아밀로이드증 시장 : 성장률 분석
- 세계의 AL 아밀로이드증 시장 실적 : 규모와 성장, 2019-2024
- 세계의 AL 아밀로이드증 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 AL 아밀로이드증 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 AL 아밀로이드증 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 화학요법
- 지지요법
- 수술
- 줄기세포 이식
- 표적치료
- 세계의 AL 아밀로이드증 시장 : 약물별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 트랜스티레틴 운송 저해제
- 면역 조절약
- 모노클로널 항체
- 프로테아좀 저해제
- 기타 약물
- 세계의 AL 아밀로이드증 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 정맥내
- 경구
- 세계의 AL 아밀로이드증 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 AL 아밀로이드증 시장, 화학요법의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 기존 화학요법제
- 고용량 화학요법
- 세계의 AL 아밀로이드증 시장, 지지요법의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 통증 관리
- 장기 특이적 지지요법(심장, 신장)
- 세계의 AL 아밀로이드증 시장, 수술의 유형별 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 장기 이식
- 감량 수술
- 세계의 AL 아밀로이드증 시장, 줄기세포 이식의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 자가 줄기세포 이식
- 동종 줄기세포 이식
- 세계의 AL 아밀로이드증 시장, 표적치료의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 모노클로널 항체
- 프로테아좀 저해제
- 키나아제 저해제
제7장 지역별·국가별 분석
- 세계의 AL 아밀로이드증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 AL 아밀로이드증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- AL 아밀로이드증 시장 : 경쟁 구도
- AL 아밀로이드증 시장 : 기업 개요
- Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Astellas Pharma Inc.
- Genmab A/S
- Alexion Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Prothena Corporation plc
- BridgeBio Pharma Inc.
- Sorrento Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- Ultromics Ltd
- Neurimmune AG
- Immix Biopharma Inc.
- Oncopeptides AB
- Attralus Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- AL 아밀로이드증 시장 2029 : 새로운 기회를 제공하는 국가
- AL 아밀로이드증 시장 2029 : 새로운 기회를 제공하는 부문
- AL 아밀로이드증 시장 2029 : 성장 전략
제36장 부록
KSA
AL Amyloidosis is a rare and serious condition where abnormal proteins, known as light chains, are produced by plasma cells in the bone marrow. These light chains misfold and form amyloid fibrils, which then accumulate in various organs and tissues, impairing their function. The heart, kidneys, liver, and nervous system are commonly affected. Symptoms depend on the organs involved but often include fatigue, swelling, shortness of breath, numbness, and organ dysfunction.
The main treatment options for AL amyloidosis include therapies such as chemotherapy, supportive care, surgery, stem cell transplants, and targeted therapy. Chemotherapy uses potent drugs to target amyloid deposits, with the goal of reducing symptoms and improving survival. These drugs include transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, and proteasome inhibitors. They can be administered intravenously or orally. In terms of distribution, these treatments are typically available through hospital pharmacies, retail pharmacies, and online pharmacies, ensuring patients can access the medications based on their needs and convenience.
The AL amyloidosis market research report is one of a series of new reports from The Business Research Company that provides AL amyloidosis market statistics, including the AL amyloidosis industry global market size, regional shares, competitors with the AL amyloidosis market share, detailed AL amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the AL amyloidosis industry. This AL amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The AL amyloidosis market size has grown rapidly in recent years. It will grow from $3.11 billion in 2024 to $3.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to increasing awareness among healthcare providers about AL amyloidosis, a rising incidence of the condition, the aging population, the expansion of diagnostic centers, and advancements in cardiac imaging.
The AL amyloidosis market size is expected to see rapid growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The expected growth in the forecast period is driven by factors such as the rise in mutations in blood cell DNA, the expansion of healthcare infrastructure, a growing incidence of multiple myeloma, the introduction of combination therapies, and an increased use of high-dose chemotherapy. Key trends during this period include advancements in diagnostic techniques, technological innovations in drug delivery, improvements in blood tests, the development of targeted therapies, and the integration of artificial intelligence (AI) in diagnosis.
The rising incidence of plasma cell disorders is expected to drive the growth of the AL amyloidosis market. Plasma cell disorders are conditions in which abnormal plasma cells produce excessive or irregular antibodies, potentially causing organ damage. Factors such as an aging population, increased life expectancy, and advancements in diagnostic technologies are contributing to the increasing incidence of these disorders. AL amyloidosis, which results from plasma cell disorders, specifically arises from the overproduction of abnormal light chain proteins. This leads to the accumulation of amyloid deposits in organs and tissues, further exacerbating the effects of plasma cell dyscrasias. For example, in August 2024, The American Cancer Society (ACS) reported that around 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024, with 19,520 in men and 16,260 in women, and approximately 12,540 deaths projected, including 7,020 men and 5,520 women. As a result, the growing prevalence of plasma cell disorders is driving the expansion of the AL amyloidosis market.
Companies in the AL amyloidosis market are focusing on developing innovative therapies, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, to enhance treatment efficacy and patient outcomes. BCMA-directed CAR T-cell therapy is an advanced immunotherapy that involves modifying a patient's T cells to target and attack BCMA on the surface of cancer cells, particularly in multiple myeloma. For instance, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for NXC-201, a next-generation CAR-T cell therapy for the treatment of the life-threatening blood disorder AL amyloidosis. NXC-201 has shown promising results in clinical trials, with a 100% hematologic response rate and organ improvements in patients who had not responded to previous treatments.
In November 2024, Stand Up To Cancer (SU2C), a US-based non-profit organization, partnered with Johnson & Johnson Inc. to advance research on novel treatments for AL amyloidosis. This collaboration aims to explore the combination of teclistamab and daratumumab as a treatment for AL amyloidosis, a rare and challenging disease, to improve therapeutic options for affected patients. Johnson & Johnson Inc., a US-based healthcare company, specializes in providing treatments for AL amyloidosis.
Major players in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, and Attralus Inc.
North America was the largest region in the AL amyloidosis market in 2024. The regions covered in AL amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the AL amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The AL amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and follow-up services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The AL amyloidosis market also includes sales of proteasome inhibitors, monoclonal antibodies, diagnostic tests, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
AL Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on al amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for al amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The al amyloidosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Chemotherapy; Supportive Care; Surgery; Stem Cell Transplant; Targeted Therapy
- 2) By Drugs: Transthyretin Transport Inhibitor; Immunomodulatory Drugs; Monoclonal Antibodies; Proteasome Inhibitors; Other Drugs
- 3) By Route Of Administration: Intravenous; Oral
- 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Chemotherapy: Conventional Chemotherapy Agents; High-Dose Chemotherapy
- 2) By Supportive Care: Pain Management; Organ-specific Supportive Care (Cardiac, Renal)
- 3) By Surgery: Organ Transplantation; Debulking Surgery
- 4) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
- 5) By Targeted Therapy: Monoclonal Antibodies; Proteasome Inhibitors; Kinase Inhibitors
- Companies Mentioned: Johnson & Johnson; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. AL Amyloidosis Market Characteristics
3. AL Amyloidosis Market Trends And Strategies
4. AL Amyloidosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global AL Amyloidosis Growth Analysis And Strategic Analysis Framework
- 5.1. Global AL Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global AL Amyloidosis Market Growth Rate Analysis
- 5.4. Global AL Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global AL Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global AL Amyloidosis Total Addressable Market (TAM)
6. AL Amyloidosis Market Segmentation
- 6.1. Global AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
- 6.2. Global AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Transthyretin Transport Inhibitor
- Immunomodulatory Drugs
- Monoclonal Antibodies
- Proteasome Inhibitors
- Other Drugs
- 6.3. Global AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous
- Oral
- 6.4. Global AL Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.5. Global AL Amyloidosis Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Conventional Chemotherapy Agents
- High-Dose Chemotherapy
- 6.6. Global AL Amyloidosis Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pain Management
- Organ-specific Supportive Care (Cardiac, Renal)
- 6.7. Global AL Amyloidosis Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Organ Transplantation
- Debulking Surgery
- 6.8. Global AL Amyloidosis Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Autologous Stem Cell Transplant
- Allogeneic Stem Cell Transplant
- 6.9. Global AL Amyloidosis Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Proteasome Inhibitors
- Kinase Inhibitors
7. AL Amyloidosis Market Regional And Country Analysis
- 7.1. Global AL Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global AL Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific AL Amyloidosis Market
- 8.1. Asia-Pacific AL Amyloidosis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China AL Amyloidosis Market
- 9.1. China AL Amyloidosis Market Overview
- 9.2. China AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India AL Amyloidosis Market
- 10.1. India AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan AL Amyloidosis Market
- 11.1. Japan AL Amyloidosis Market Overview
- 11.2. Japan AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia AL Amyloidosis Market
- 12.1. Australia AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia AL Amyloidosis Market
- 13.1. Indonesia AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea AL Amyloidosis Market
- 14.1. South Korea AL Amyloidosis Market Overview
- 14.2. South Korea AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe AL Amyloidosis Market
- 15.1. Western Europe AL Amyloidosis Market Overview
- 15.2. Western Europe AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK AL Amyloidosis Market
- 16.1. UK AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany AL Amyloidosis Market
- 17.1. Germany AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France AL Amyloidosis Market
- 18.1. France AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy AL Amyloidosis Market
- 19.1. Italy AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain AL Amyloidosis Market
- 20.1. Spain AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe AL Amyloidosis Market
- 21.1. Eastern Europe AL Amyloidosis Market Overview
- 21.2. Eastern Europe AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia AL Amyloidosis Market
- 22.1. Russia AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America AL Amyloidosis Market
- 23.1. North America AL Amyloidosis Market Overview
- 23.2. North America AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA AL Amyloidosis Market
- 24.1. USA AL Amyloidosis Market Overview
- 24.2. USA AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada AL Amyloidosis Market
- 25.1. Canada AL Amyloidosis Market Overview
- 25.2. Canada AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America AL Amyloidosis Market
- 26.1. South America AL Amyloidosis Market Overview
- 26.2. South America AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil AL Amyloidosis Market
- 27.1. Brazil AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East AL Amyloidosis Market
- 28.1. Middle East AL Amyloidosis Market Overview
- 28.2. Middle East AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa AL Amyloidosis Market
- 29.1. Africa AL Amyloidosis Market Overview
- 29.2. Africa AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. AL Amyloidosis Market Competitive Landscape And Company Profiles
- 30.1. AL Amyloidosis Market Competitive Landscape
- 30.2. AL Amyloidosis Market Company Profiles
- 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
31. AL Amyloidosis Market Other Major And Innovative Companies
- 31.1. Takeda Pharmaceutical Company Limited
- 31.2. Boehringer Ingelheim International GmbH
- 31.3. Astellas Pharma Inc.
- 31.4. Genmab A/S
- 31.5. Alexion Pharmaceuticals Inc.
- 31.6. Alnylam Pharmaceuticals Inc.
- 31.7. Prothena Corporation plc
- 31.8. BridgeBio Pharma Inc.
- 31.9. Sorrento Therapeutics Inc.
- 31.10. Ionis Pharmaceuticals Inc.
- 31.11. Ultromics Ltd
- 31.12. Neurimmune AG
- 31.13. Immix Biopharma Inc.
- 31.14. Oncopeptides AB
- 31.15. Attralus Inc.
32. Global AL Amyloidosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The AL Amyloidosis Market
34. Recent Developments In The AL Amyloidosis Market
35. AL Amyloidosis Market High Potential Countries, Segments and Strategies
- 35.1 AL Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 AL Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 AL Amyloidosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
